Social Media Ideas for Natco Pharma Ltd

NATCO Pharma Stock in Focus After Receiving USFDA Approval For Cancer Drug With Lupin

Synopsis: NATCO Pharma and its alliance partner Lupin have received USFDA approval for Eribulin Mesylate Injection, a generic version of Eisai’s Halaven used in the treatment of me...

Natco Pharma’s Q4 net down 34% at ₹269 cr

The total revenue of the Hyderabad - based company too declined 36.5 percent at Rs ₹816 crore against Rs ₹1287 crore in the year ago period. 

Natco Pharma to raise stake in Adcock Ingram to 49% with ₹1,400 crore investment

This acquisition is valued at ₹1,069 crore and will take Hyderabad-based Natco’s shareholding in Adcock Ingram from 35.75 percent to 49 percent

Dr Reddy’s launches Bosutinib tablets in US market

The company has collaborated with MSN Laboratories on the product

IPCA Labs, Biocon, Laurus Labs, Gland Pharma, Aurobindo, Sun Pharma shares hit 52-week highs; what's next?

Other pharma stocks, including Wockhardt Ltd, Lupin Ltd, Divi's Laboratories Ltd, Zydus Lifesciences Ltd, Torrent Pharmaceuticals Ltd, JB Chemicals & Pharmaceuticals Ltd, Manki...

Sun Pharma to acquire Innovcare Lifesciences in ₹271 crore deal

Lilly launches cancer therapy Tanstrive for patients with advanced or metastatic solid tumors with a RET gene alteration

Twice a day oral drug is priced at ₹2.15 lakh for two weeks treatment

Patni family’s pharma foray: Raay Neo looks at smaller cities, less expensive medicines

Patni family venture to price medicines 15-20 per cent lower and target ₹1,000 crore revenue in five years

Hetero Pharma to recruit over 300 Intermediate candidates

Akums Reports Q4 FY26 and Full Year FY26 Results with Healthy Top Line and Strong EBITDA Growth; Board Recommends Divide...

NewsVoirNew Delhi [India], May 15: Akums Drugs & Pharmaceuticals Ltd., India's largest Contract Development and Manufacturing Organisation (CDMO), announced its financial resul...

Akums Reports Q4 FY26 and Full Year FY26 Results with Healthy Top Line and Strong EBITDA Growth; Board Recommends Divide...

NewsVoirNew Delhi [India], May 15: Akums Drugs & Pharmaceuticals Ltd., India's largest Contract Development and Manufacturing Organisation (CDMO), announced its financial resul...

Pharma Stock Jumps After Securing ₹515 Cr Contracts from Malaysia’s Ministry of Health

Synopsis: Biocon strengthened its Malaysia presence after partner Duopharma secured insulin contracts worth over ₹514 crore, supporting affordable diabetes treatment and expanding...

<![CDATA[Catalent Announces Expanded Partnership with Nanoscope Therapeutics]]>

Handa, Intas Face Patent Suits Over Exelixis Cancer Drug

Handa Pharmaceuticals and Intas Pharmaceuticals are wrongly trying to bring to market drugs that would compete with Exelixis Inc.'s blockbuster cancer pill Cabometyx before patents...

After early Semaglutide lead, Torrent Pharma eyes US liver drug Resmetirom for India launch

Resmetirom is the first approved therapy in the US specifically for MASH, earlier known as NASH—a progressive fatty liver disease linked to obesity, diabetes and poor metabolic hea...

Granules India gets First-To-File status for generic Lumryz tablets in US

This was Granules’ second Sole First-to-File ANDA, following its earlier approval for Amphetamine Extended-Release Tablets,

Pharma Stock Jumps 10% After Securing Japanese Patent for Cancer Treatment Compound

Synopsis: Shares surged 10% after the company secured a Japanese patent for a novel cancer-treatment compound. The patent covers compounds effective against cancer and cancer stem...

Marksans Pharma acquires German OTC distributor ABCnow GmbH for €892,384

The acquisition gives Marksans direct front-end sales and distribution infrastructure in Germany, which will be used for marketing products manufactured across its India, UK, and U...

Pharma industry body scouts for Indian suppliers as US faces cancer drug shortage

 Industry body reaches out to members for information on ifosfamide manufacturing capacity amid shortage in the United States

Gland Pharma, Sun Pharmaceutical, Laurus Labs shares zoom up to 16% to hit 52-week highs; here's why

Gland Pharma jumped 15.85 per cent to Rs 2,164.40, while Sun Pharma climbed 1 per cent to Rs 1,896.90. Laurus Labs moved up 0.63 per cent to Rs 1,332.

Pharma Stock to Buy Now for an Upside of 29%; Recommended by Citi

Synopsis: Citi maintained a Buy rating on Divi’s Laboratories with a ₹9,450 target, citing capacity expansion, new product launches, and strong long-term earnings growth. This Larg...

The blockbuster drug India can now actually afford

With Novo Nordisk's patent gone in India, a dozen generics have flooded in at a fraction of the price, and a market of 10 crore diabetics is waiting

5 Indian CDMO Stocks Benefiting from the Global Pharma Outsourcing Boom

Synopsis: Global pharmaceutical companies are rapidly diversifying their manufacturing supply chains as geopolitical tensions, regulatory changes and the proposed U.S. BIOSECURE Ac...

Gland Pharma: What should you do?

Margin improvement from higher value-added products and expanding portfolio should support earnings growth